Gritstone Bio Price to Sales Ratio 2017-2022 | GRTS

Historical PS ratio values for Gritstone Bio (GRTS) over the last 10 years. The current P/S ratio for Gritstone Bio as of July 01, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Gritstone Bio P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-07-01 2.46 12.76
2022-03-31 4.12 $0.19 21.36
2021-12-31 12.86 $0.62 20.68
2021-09-30 10.80 $0.62 17.46
2021-06-30 9.13 $0.61 14.97
2021-03-31 9.43 $0.59 16.09
2020-12-31 3.94 $0.11 36.50
2020-09-30 2.65 $0.10 26.87
2020-06-30 6.64 $0.10 65.54
2020-03-31 5.82 $0.12 47.53
2019-12-31 8.97 $0.13 66.59
2019-09-30 8.64 $0.23 37.43
2019-06-30 11.14 $0.24 45.96
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.179B $0.048B
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00